Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Geron halts its late-stage IMpactMF trial after an independent monitoring committee determined that Rytelo was unlikely to demonstrate a survival benefit over standard therapy in myelofibrosis patients. The news sent Geron's shares tumbling ~20%. Analysts remain cautiously optimistic, noting no new safety signals and that Rytelo's approved use in lower-risk myelodysplastic syndromes stays intact.
Geron has discontinued its IMpactMF trial — a late-stage study evaluating its blood cancer drug Rytelo (imetelstat) in patients with high-risk myelofibrosis whose disease had relapsed or failed to respond to a JAK inhibitor. The decision came after an independent data monitoring committee concluded the trial was unlikely to meet its primary endpoint of overall survival compared to best available therapy. Shares dropped roughly 20% on the news.
The trial enrolled 327 patients, and while the survival data disappointed, Geron noted no new safety concerns — even at the higher and more frequent doses used in this study compared to its approved indication. Analysts from TD Cowen and Wedbush were measured in their response, suggesting the setback doesn't fundamentally undermine Rytelo's commercial story in its approved setting.
By the Numbers:
Why it matters: Rytelo remains the only approved treatment for transfusion-dependent anemia in lower-risk myelodysplastic syndromes, and this trial failure doesn't affect that label. However, the setback narrows Geron's growth runway and raises questions about the drug's potential beyond its current indication.
